Prostate Cancer

Top Story

Brachytherapy alone can control intermediate-risk prostate cancer

Brachytherapy alone can control intermediate-risk prostate cancer
September 27, 2016

Read the Perspective from Colleen Lawton, MD, FASTRO

The addition of external beam therapy to brachytherapy did not significantly extend PFS among men with intermediate-risk prostate cancer, according to the initial report of a phase 3 study presented at the ASTRO Annual Meeting.

Thus, radiation treatment with brachytherapy alone may provide adequate cancer control for this population, resulting in fewer long-term adverse events, results showed.

Meeting News Coverage

Financial burdens more common in black cancer survivors

September 26, 2016
Black cancer survivors appeared more likely than white survivors to face lasting debt and limit their medical care due to cost concerns, according to study results…
Editorial

Treating the primary in metastatic prostate cancer

HemOnc Today, September 25, 2016
Derek Raghavan, MD, PhD
Rusthoven and colleagues recently reported a post-hoc analysis of 6,382 men with newly diagnosed metastatic prostate cancer treated with androgen deprivation therapy, of…

Five important updates in prostate cancer

September 23, 2016
National Prostate Cancer Awareness Month, observed in September, is intended to educate men about disease risk factors, screening options and other matters related to…
CME

The Patient with Multiple Ecchymoses

No commercial support for this activity.

Glanzmann’s thrombasthenia is a rare, inherited bleeding disorder that results from a mutation in αIIbß3, an integrin…
More »
Video
At Issue

VIDEO: Toxicities related to immune therapies ‘unpredictable’ but ‘manageable’

June 23, 2016
More »
Featured
At Issue: Breast Cancer Resource Center

At Issue: Breast Cancer Resource Center

CME CNE CPE

Individualized Prophylaxis in Hemophilia

Support for this activity has been made possible through an educational grant from Bayer HealthCare Pharmaceuticals

This program will provide education for hematologists, nurses, pharmacists, and other healthcare providers involved in…
More »
Meeting News CoveragePerspective

Brachytherapy alone can control intermediate-risk prostate cancer

September 27, 2016
The addition of external beam therapy to brachytherapy did not significantly extend PFS among men with intermediate-risk prostate cancer, according…

Meeting News Coverage

Financial burdens more common in black cancer survivors

September 26, 2016
Black cancer survivors appeared more likely than white survivors to face lasting debt and limit their medical care due to cost concerns, according to…

Editorial

Treating the primary in metastatic prostate cancer

HemOnc Today, September 25, 2016
Derek Raghavan, MD, PhD
Rusthoven and colleagues recently reported a post-hoc analysis of 6,382 men with newly diagnosed metastatic prostate cancer treated with androgen…

Five important updates in prostate cancer

September 23, 2016
National Prostate Cancer Awareness Month, observed in September, is intended to educate men about disease risk factors, screening options and other…

In the Journals Plus

Opioid-induced constipation medication may improve OS in advanced cancer

September 22, 2016
Treatment with and response to methylnaltrexone for opioid-induced constipation appeared associated with improved OS in patients with advanced…

Perspective

AACR report: Sustained federal commitment required to accelerate cancer research progress

September 20, 2016
Extraordinary therapeutic advances, a renewed bipartisan commitment to medical research and the launch of the national cancer moonshot initiative…

In the Journals Plus

Vasectomy does not increase risk for prostate cancer incidence, mortality

September 19, 2016
Men who underwent vasectomy did not demonstrate an increased risk for prostate cancer incidence or mortality, according to an analysis of large…

Biden announces steps to improve clinical trials under cancer moonshot

September 19, 2016
Vice President Joe Biden outlined a plan to improve the efficiency and transparency of the U.S. clinical research system as part of the national…

In the Journals Plus

Active monitoring, treatment confer comparable prostate cancer–specific survival

September 15, 2016
Active monitoring demonstrated comparable rates of disease-specific mortality but worse rates of disease progression and metastases compared with…

Cover Story

Proton beam therapy at ‘tipping point’ due to inconsistent reimbursement, lack of comparative data

HemOnc Today, September 10, 2016
The FDA approved the first generation of proton beam therapy nearly 30 years ago. Despite tremendous enthusiasm about the modality’s potential…

More Headlines »
morganatic-roan
morganatic-roan